DE602005002930D1 - Sulfonamidderivate zur behandlung von krankheiten - Google Patents

Sulfonamidderivate zur behandlung von krankheiten

Info

Publication number: DE602005002930D1
Authority: DE; Germany
Prior art keywords: diseases; treatment; sulfonamide derivatives; sulfonamide; derivatives
Prior art date: 2004-01-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

DE602005002930T

Other languages

English (en)

Other versions

DE602005002930T2 (de

Inventor

Alan D Brown

Mark E Bunnage

Paul A Glossop

Kim James

Charlotte A L Lane

Russell A Lewthwaite

Ian B Moses

David A Price

Nicholas M Thomson

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pfizer Inc

Original Assignee

Pfizer Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-01-22

Filing date

2005-01-12

Publication date

2007-11-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36954179&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602005002930(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-03-22 Priority claimed from GB0406387A external-priority patent/GB0406387D0/en

2005-01-12 Application filed by Pfizer Inc filed Critical Pfizer Inc

2007-11-29 Publication of DE602005002930D1 publication Critical patent/DE602005002930D1/de

2008-07-24 Application granted granted Critical

2008-07-24 Publication of DE602005002930T2 publication Critical patent/DE602005002930T2/de

Status Active legal-status Critical Current

2025-01-13 Anticipated expiration legal-status Critical

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

DE602005002930T 2004-01-22 2005-01-12 Sulfonamidderivate zur behandlung von krankheiten Active DE602005002930T2 (de)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
EP04290169		2004-01-22
EP04290169		2004-01-22
GB0406387A GB0406387D0 (en)	2004-03-22	2004-03-22	Sulfonamide derivatives for the treatment of diseases
GB0406387		2004-03-22
US60026004P	2004-08-09	2004-08-09
US600260P		2004-08-09
PCT/IB2005/000086 WO2005080313A2 (en)	2004-01-22	2005-01-12	Sulfonamide derivatives for the treatment of diseases

Publications (2)

Publication Number	Publication Date
DE602005002930D1 true DE602005002930D1 (de)	2007-11-29
DE602005002930T2 DE602005002930T2 (de)	2008-07-24

Family

ID=36954179

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE602005002930T Active DE602005002930T2 (de)	2004-01-22	2005-01-12	Sulfonamidderivate zur behandlung von krankheiten

Country Status (30)

Country	Link
US (4)	US7244766B2 (de)
EP (1)	EP1708991B1 (de)
JP (1)	JP4020954B2 (de)
AP (1)	AP2359A (de)
AR (1)	AR047509A1 (de)
AT (1)	ATE375977T1 (de)
AU (1)	AU2005214153B2 (de)
BR (1)	BRPI0507085A (de)
CA (1)	CA2553789C (de)
DE (1)	DE602005002930T2 (de)
DK (1)	DK1708991T3 (de)
DO (1)	DOP2005000006A (de)
EA (1)	EA011167B1 (de)
ES (1)	ES2293530T3 (de)
GE (1)	GEP20094781B (de)
MY (1)	MY143390A (de)
NL (1)	NL1028087C2 (de)
NO (1)	NO20062983L (de)
NZ (1)	NZ548318A (de)
OA (1)	OA13362A (de)
PA (1)	PA8622001A1 (de)
PE (1)	PE20051136A1 (de)
PL (1)	PL1708991T3 (de)
PT (1)	PT1708991E (de)
RS (1)	RS50561B (de)
SI (1)	SI1708991T1 (de)
TW (1)	TWI341831B (de)
UA (1)	UA84048C2 (de)
UY (1)	UY28721A1 (de)
WO (1)	WO2005080313A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS50561B (sr) *	2004-01-22	2010-05-07	Pfizer Inc.	Derivati sulfonamida za lečenje bolesti
GB0425054D0 (en) *	2004-03-23	2004-12-15	Pfizer Ltd	Formamide derivatives for the treatment of diseases
GT200500281A (es)	2004-10-22	2006-04-24	Novartis Ag	Compuestos organicos.
EP1695973A1 (de) *	2005-02-24	2006-08-30	Neuro3D	Ocaperidonsalz und dieser enthaltende pharmazeutische Zubereitung
EP1907356A2 (de) *	2005-07-18	2008-04-09	Pfizer Limited	Verfahren zur herstellung von sulfonamidderivaten
CA2618089A1 (en)	2005-08-08	2007-02-15	Argenta Discovery Ltd.	Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
GB0516313D0 (en)	2005-08-08	2005-09-14	Argenta Discovery Ltd	Azole derivatives and their uses
GB0601951D0 (en)	2006-01-31	2006-03-15	Novartis Ag	Organic compounds
DK2013211T3 (da)	2006-04-21	2012-07-02	Novartis Ag	Purinderivater til anvendelse som adenosin-A2A-receptoragonister
JP4948913B2 (ja) *	2006-06-16	2012-06-06	上野製薬株式会社	ナフタレンカルボン酸アミドの製造方法
PL2231642T3 (pl)	2008-01-11	2014-04-30	Novartis Ag	Pirymidyny jako inhibitory kinazy
US8236786B2 (en)	2008-08-07	2012-08-07	Pulmagen Therapeutics (Inflammation) Limited	Respiratory disease treatment
AU2009334597B2 (en)	2008-12-30	2015-07-16	Pulmagen Therapeutics (Inflammation) Limited	Sulfonamide compounds for the treatment of respiratory disorders
EP2435462A1 (de)	2009-05-29	2012-04-04	Pfizer Limited	Neue glucocorticoidrezeptoragonisten
WO2010150014A1 (en)	2009-06-24	2010-12-29	Pulmagen Therapeutics (Inflammation) Limited	5r- 5 -deuterated glitazones for respiratory disease treatment
JP5801997B2 (ja)	2009-07-07	2015-10-28	ファイザー・リミテッドＰｆｉｚｅｒＬｉｍｉｔｅｄ	薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
GB0918922D0 (en)	2009-10-28	2009-12-16	Vantia Ltd	Aminopyridine derivatives
GB0918923D0 (en)	2009-10-28	2009-12-16	Vantia Ltd	Aminothiazole derivatives
GB0918924D0 (en)	2009-10-28	2009-12-16	Vantia Ltd	Azaindole derivatives
WO2011098746A1 (en)	2010-02-09	2011-08-18	Pulmagen Therapeutics (Inflammation) Limited	Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002224D0 (en)	2010-02-10	2010-03-31	Argenta Therapeutics Ltd	Respiratory disease treatment
GB201002243D0 (en)	2010-02-10	2010-03-31	Argenta Therapeutics Ltd	Respiratory disease treatment
WO2012034095A1 (en)	2010-09-09	2012-03-15	Irm Llc	Compounds and compositions as trk inhibitors
US8637516B2 (en)	2010-09-09	2014-01-28	Irm Llc	Compounds and compositions as TRK inhibitors
MA34969B1 (fr)	2011-02-25	2014-03-01	Irm Llc	Composes et compositions en tant qu inibiteurs de trk
WO2013021309A1 (en)	2011-08-11	2013-02-14	Pfizer Limited	Intermediate and process for the preparation of a sulfonamide derivative
AU2021296221A1 (en)	2020-06-26	2023-02-02	Mylan Pharma Uk Limited	Formulations including 5-(3-(3-hydroxyphenoxy)azetidin-1-yl)-5-methyl-2,2-diphenylhexanamide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US143034A (en) *		1873-09-23		Improvement in rocking-grates
US229058A (en) *		1880-06-22		spencer
US4404224A (en)	1981-12-02	1983-09-13	American Cyanamid Company	Alkanesulfonanilide derivatives and pharmaceutically acceptable acid addition salts thereof for increasing the growth rate and/or improving the lean meat to fat ratio of warm blooded animals
US4540581A (en) *	1984-01-31	1985-09-10	Bristol-Myers Company	Topical nonsteroidal anti-inflammatory compositions and uses
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5264067A (en)	1992-04-23	1993-11-23	Geber Garment Technology, Inc.	Adjustable length carriage compatible for use with differing spreading table widths and types
US5776983A (en) *	1993-12-21	1998-07-07	Bristol-Myers Squibb Company	Catecholamine surrogates useful as β3 agonists
SE9700135D0 (sv) *	1997-01-20	1997-01-20	Astra Ab	New formulation
JPH10218861A (ja)	1997-02-04	1998-08-18	Yamanouchi Pharmaceut Co Ltd	新規なフェネタノール誘導体又はその塩
GB9711643D0 (en)	1997-06-05	1997-07-30	Janssen Pharmaceutica Nv	Glass thermoplastic systems
KR20010014183A (ko) *	1997-06-27	2001-02-26	Fujisawa Pharmaceutical Co	술폰아미드 화합물 및 그의 의약 용도
US6541669B1 (en)	1998-06-08	2003-04-01	Theravance, Inc.	β2-adrenergic receptor agonists
US20020143034A1 (en) *	1998-12-30	2002-10-03	Fujisawa Pharmaceutical Co. Ltd.	Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
AUPQ841300A0 (en)	2000-06-27	2000-07-20	Fujisawa Pharmaceutical Co., Ltd.	New aminoalcohol derivatives
US6465501B2 (en)	2000-07-17	2002-10-15	Wyeth	Azolidines as β3 adrenergic receptor agonists
HRP20000765A2 (en) *	2000-11-10	2002-06-30	Pliva D D	Compositions of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides with increased release
US7048994B2 (en)	2001-02-23	2006-05-23	Teijin Limited	Laminated polyester film and magnetic recording medium
US20030229058A1 (en) *	2001-11-13	2003-12-11	Moran Edmund J.	Aryl aniline beta2 adrenergic receptor agonists
DE10244972B4 (de) *	2002-03-26	2013-02-28	The Japan Steel Works, Ltd.	Wärmefester Stahl und Verfahren zur Herstellung desselben
EP1507754A1 (de) *	2002-05-28	2005-02-23	Theravance, Inc.	Alkoxy aryl beta-2 adrenergen rezeptoragonisten
EP1477167A1 (de) *	2003-05-15	2004-11-17	Pfizer Limited	[(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivative als beta2 agonist
RS50561B (sr) *	2004-01-22	2010-05-07	Pfizer Inc.	Derivati sulfonamida za lečenje bolesti

2005
- 2005-01-12 RS RSP-2007/0488A patent/RS50561B/sr unknown
- 2005-01-12 EP EP05702252A patent/EP1708991B1/de active Active
- 2005-01-12 DK DK05702252T patent/DK1708991T3/da active
- 2005-01-12 EA EA200601223A patent/EA011167B1/ru not_active IP Right Cessation
- 2005-01-12 PT PT05702252T patent/PT1708991E/pt unknown
- 2005-01-12 WO PCT/IB2005/000086 patent/WO2005080313A2/en active Application Filing
- 2005-01-12 SI SI200530103T patent/SI1708991T1/sl unknown
- 2005-01-12 CA CA2553789A patent/CA2553789C/en not_active Expired - Fee Related
- 2005-01-12 NZ NZ548318A patent/NZ548318A/en not_active IP Right Cessation
- 2005-01-12 DE DE602005002930T patent/DE602005002930T2/de active Active
- 2005-01-12 OA OA1200600234A patent/OA13362A/en unknown
- 2005-01-12 AU AU2005214153A patent/AU2005214153B2/en not_active Ceased
- 2005-01-12 JP JP2006550327A patent/JP4020954B2/ja not_active Expired - Fee Related
- 2005-01-12 PL PL05702252T patent/PL1708991T3/pl unknown
- 2005-01-12 GE GEAP20059536A patent/GEP20094781B/en unknown
- 2005-01-12 BR BRPI0507085-6A patent/BRPI0507085A/pt not_active IP Right Cessation
- 2005-01-12 ES ES05702252T patent/ES2293530T3/es active Active
- 2005-01-12 AP AP2006003669A patent/AP2359A/xx active
- 2005-01-12 UA UAA200608227A patent/UA84048C2/ru unknown
- 2005-01-12 AT AT05702252T patent/ATE375977T1/de active
- 2005-01-18 MY MYPI20050197A patent/MY143390A/en unknown
- 2005-01-18 TW TW094101443A patent/TWI341831B/zh not_active IP Right Cessation
- 2005-01-19 UY UY28721A patent/UY28721A1/es not_active Application Discontinuation
- 2005-01-19 US US11/038,452 patent/US7244766B2/en not_active Expired - Fee Related
- 2005-01-20 AR ARP050100205A patent/AR047509A1/es unknown
- 2005-01-20 DO DO2005000006A patent/DOP2005000006A/es unknown
- 2005-01-20 PE PE2005000079A patent/PE20051136A1/es not_active Application Discontinuation
- 2005-01-21 PA PA20058622001A patent/PA8622001A1/es unknown
- 2005-01-21 NL NL1028087A patent/NL1028087C2/nl not_active IP Right Cessation
2006
- 2006-06-27 NO NO20062983A patent/NO20062983L/no not_active Application Discontinuation
2007
- 2007-07-03 US US11/772,995 patent/US7528170B2/en not_active Expired - Fee Related
2009
- 2009-04-08 US US12/420,206 patent/US7767715B2/en not_active Expired - Fee Related
2010
- 2010-07-01 US US12/828,762 patent/US8013019B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO2005080313A2 (en)	2005-09-01
AU2005214153B2 (en)	2008-09-18
WO2005080313A9 (en)	2006-08-31
EP1708991B1 (de)	2007-10-17
US20080267970A1 (en)	2008-10-30
GEP20094781B (en)	2009-09-25
UY28721A1 (es)	2005-08-31
RS50561B (sr)	2010-05-07
US20090197912A1 (en)	2009-08-06
TWI341831B (en)	2011-05-11
PE20051136A1 (es)	2006-02-18
DOP2005000006A (es)	2005-07-31
EA011167B1 (ru)	2009-02-27
PL1708991T3 (pl)	2008-02-29
WO2005080313A3 (en)	2005-12-01
DE602005002930T2 (de)	2008-07-24
PA8622001A1 (es)	2005-08-30
NO20062983L (no)	2006-07-24
US7528170B2 (en)	2009-05-05
EP1708991A2 (de)	2006-10-11
ES2293530T3 (es)	2008-03-16
JP2007518789A (ja)	2007-07-12
US20100273758A1 (en)	2010-10-28
DK1708991T3 (da)	2008-01-14
TW200530165A (en)	2005-09-16
OA13362A (en)	2007-04-13
SI1708991T1 (sl)	2008-02-29
CA2553789A1 (en)	2005-09-01
AR047509A1 (es)	2006-01-25
AU2005214153A1 (en)	2005-09-01
US8013019B2 (en)	2011-09-06
JP4020954B2 (ja)	2007-12-12
AP2359A (en)	2012-01-30
NL1028087C2 (nl)	2006-05-09
BRPI0507085A (pt)	2007-06-19
CA2553789C (en)	2011-07-19
US20050182091A1 (en)	2005-08-18
NL1028087A1 (nl)	2005-07-25
UA84048C2 (ru)	2008-09-10
AP2006003669A0 (en)	2006-06-30
EA200601223A1 (ru)	2006-12-29
MY143390A (en)	2011-05-13
US7767715B2 (en)	2010-08-03
ATE375977T1 (de)	2007-11-15
PT1708991E (pt)	2007-12-14
NZ548318A (en)	2009-03-31
US7244766B2 (en)	2007-07-17

Legal Events

Date

Code

Title

Description

2008-07-03

8381

Inventor (new situation)

Inventor name: MOSES, IAN B., SANDWICH, KENT, GB

Inventor name: THOMSON, NICHOLAS M., SANDWICH, KENT, GB

Inventor name: PRICE, DAVID A., SANDWICH, KENT, GB

Inventor name: BROWN, ALAN D., SANDWICH, KENT, GB

Inventor name: BUNNAGE, MARK E., SANDWICH, KENT, GB

Inventor name: LEWTHWAITE, RUSSELL A., SANDWICH, KENT, GB

Inventor name: JAMES, KIM, SANDWICH, KENT, GB

Inventor name: GLOSSOP, PAUL A., SANDWICH, KENT, GB

Inventor name: LANE, CHARLOTTE A.L., SANDWICH, KENT, GB

2008-11-06

8364

No opposition during term of opposition

Publication	Publication Date	Title
ATE369333T1 (de)	2007-08-15	Sulfonamidderivate zur behandlung von krankheiten
ATE375977T1 (de)	2007-11-15	Sulfonamidderivate zur behandlung von krankheiten
DE602005023172D1 (de)	2010-10-07	Hydantoinderivate zur behandlung von entzündlichen erkrankungen
DE602005007717D1 (de)	2008-08-07	Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
DE602005005810D1 (de)	2008-05-15	Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
DE602005026984D1 (de)	2011-04-28	Chinolin-derivate zur behandlung von latenter tuberkulose
DE602004028763D1 (de)	2010-09-30	Te zur behandlung von virenerkrankungen
ATE512663T1 (de)	2011-07-15	Kombination zur behandlung von erkrankungen mit zellproliferation
ATE527241T1 (de)	2011-10-15	Pyridiazinonderivate zur behandlung von tumoren
ATE476414T1 (de)	2010-08-15	Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
DE602005017503D1 (de)	2009-12-17	Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
DE60303238D1 (de)	2006-04-06	Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
ATE550338T1 (de)	2012-04-15	Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE550329T1 (de)	2012-04-15	Heterobicyclische sulfonamidderivate zur behandlung von diabetes
ATE534633T1 (de)	2011-12-15	Indazolderivate zur behandlung von hsp90- induzierten krankheiten
ATE482709T1 (de)	2010-10-15	Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen
ATE443704T1 (de)	2009-10-15	Pyridopyrimidinone zur behandlung von krebserkrankungen
DE602006003094D1 (de)	2008-11-20	4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
DE602005016141D1 (de)	2009-10-01	S-mirtazapin zur behandlung von hitzewallungen
ATE504297T1 (de)	2011-04-15	Visnadin zur behandlung von kopfhautjucken
ATE526970T1 (de)	2011-10-15	Behandlung von mastitis
DE602007009877D1 (de)	2010-11-25	Isosorbid-mononitrat-derivate zur behandlung von darmerkrankungen
ATE503752T1 (de)	2011-04-15	Sulfamide alsendothelinrezeptorantagonsiten zur behandlung von herzkreislauferkrankungen
ATE525355T1 (de)	2011-10-15	1-ä(4-äbenzoyl(methyl)aminoü-3- (phenyl)butylüazetidinderivate zur behandlung von gastrointestinalen erkrankungen 1
ATE482707T1 (de)	2010-10-15	1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen